MD3484467T2 - Combinație de antagoniști ai receptorilor 5-HT6 puri cu inhibitori ai acetilcolinesterazei - Google Patents

Combinație de antagoniști ai receptorilor 5-HT6 puri cu inhibitori ai acetilcolinesterazei

Info

Publication number
MD3484467T2
MD3484467T2 MDE20190594T MDE20190594T MD3484467T2 MD 3484467 T2 MD3484467 T2 MD 3484467T2 MD E20190594 T MDE20190594 T MD E20190594T MD E20190594 T MDE20190594 T MD E20190594T MD 3484467 T2 MD3484467 T2 MD 3484467T2
Authority
MD
Moldova
Prior art keywords
combination
pure
receptor antagonists
acetylcholinesterase inhibitors
relates
Prior art date
Application number
MDE20190594T
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Pradeep Jayarajan
Gopinadh Bhyrapuneni
Ramasastri Kambhampati
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MD3484467T2 publication Critical patent/MD3484467T2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

Prezenta invenţie se referă la antagonişti ai receptorilor 5-HT6 puri (5-HT6R) sau la sărurile lor acceptabile farmaceutic în combinaţie cu sau pe lângă inhibitorii acetilcolinesterazei şi la utilizarea acestora în tratarea bolilor cognitive. Invenţia se referă de asemenea la compoziţia farmaceutică ce conţine combinaţia respectivă.
MDE20190594T 2016-05-18 2016-08-03 Combinație de antagoniști ai receptorilor 5-HT6 puri cu inhibitori ai acetilcolinesterazei MD3484467T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641017205 2016-05-18
PCT/IB2016/054673 WO2017199071A1 (en) 2016-05-18 2016-08-03 Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
MD3484467T2 true MD3484467T2 (ro) 2020-06-30

Family

ID=56940098

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20190594T MD3484467T2 (ro) 2016-05-18 2016-08-03 Combinație de antagoniști ai receptorilor 5-HT6 puri cu inhibitori ai acetilcolinesterazei

Country Status (28)

Country Link
US (1) US11458135B2 (ro)
EP (1) EP3484467B1 (ro)
JP (1) JP6606299B2 (ro)
KR (1) KR102015484B1 (ro)
CN (2) CN114642667A (ro)
AU (1) AU2016407427B2 (ro)
BR (1) BR112018073419A2 (ro)
CA (1) CA3023819C (ro)
CY (1) CY1123013T1 (ro)
DK (1) DK3484467T3 (ro)
EA (1) EA036347B1 (ro)
ES (1) ES2796181T3 (ro)
HR (1) HRP20200872T1 (ro)
HU (1) HUE050819T2 (ro)
IL (1) IL262921B (ro)
LT (1) LT3484467T (ro)
MA (1) MA45639B1 (ro)
MD (1) MD3484467T2 (ro)
ME (1) ME03731B (ro)
MX (1) MX2018014185A (ro)
NZ (1) NZ748280A (ro)
PL (1) PL3484467T3 (ro)
PT (1) PT3484467T (ro)
RS (1) RS60422B1 (ro)
SG (1) SG11201809856SA (ro)
SI (1) SI3484467T1 (ro)
WO (1) WO2017199071A1 (ro)
ZA (1) ZA201807468B (ro)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111084768A (zh) * 2018-10-24 2020-05-01 中国科学院昆明动物研究所 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途
CN111084776A (zh) * 2018-10-24 2020-05-01 中国科学院昆明动物研究所 匹立尼酸及其衍生物用于治疗和/或预防神经退行性疾病的用途
JP7556031B2 (ja) * 2019-12-02 2024-09-25 スヴェン・ライフ・サイエンシーズ・リミテッド 認知症患者の行動心理学的症状の治療
BR112022010540A2 (pt) 2019-12-02 2022-08-16 Suven Life Sciences Ltd Métodos para tratar sintomas comportamentais e psicológicos em pacientes com demência

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1581492T3 (da) * 2002-11-28 2008-11-10 Suven Life Sciences Ltd N-arylsulfonyl-3-substituerede indoler med serotoninreceptoraffinitet, fremgangsmåde til fremstilling heraf og en farmaceutisk sammensætning indeholdende disse
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
MX2008015996A (es) * 2006-06-23 2009-01-20 Esteve Labor Dr Combinacion de un inhibidor de la colinesterasa y un compuesto con afinidad por el receptor 5-ht6.
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
ME02843B (me) 2013-12-02 2018-01-20 Suven Life Sciences Ltd Proces za masovnu proizvodnju monohidrata 1- [(2-bromofenil)sulfonil]-5-metoksi-3-[( 4- metil- 1-piperazinil)metil]-1h-indol dimezilata

Also Published As

Publication number Publication date
IL262921B (en) 2020-05-31
MX2018014185A (es) 2019-02-25
LT3484467T (lt) 2020-07-10
PT3484467T (pt) 2020-06-16
DK3484467T3 (da) 2020-06-08
KR102015484B1 (ko) 2019-08-28
US20190125743A1 (en) 2019-05-02
SI3484467T1 (sl) 2020-10-30
ZA201807468B (en) 2020-02-26
RS60422B1 (sr) 2020-07-31
PL3484467T3 (pl) 2020-08-24
US11458135B2 (en) 2022-10-04
AU2016407427B2 (en) 2019-11-21
CN109069468A (zh) 2018-12-21
BR112018073419A2 (pt) 2019-03-19
ME03731B (me) 2021-01-20
EA201892529A1 (ru) 2019-03-29
CY1123013T1 (el) 2021-10-29
CN114642667A (zh) 2022-06-21
JP6606299B2 (ja) 2019-11-13
CA3023819A1 (en) 2017-11-23
HRP20200872T1 (hr) 2020-11-27
HUE050819T2 (hu) 2021-01-28
EA036347B1 (ru) 2020-10-29
IL262921A (en) 2018-12-31
EP3484467B1 (en) 2020-04-29
WO2017199071A1 (en) 2017-11-23
SG11201809856SA (en) 2018-12-28
EP3484467A1 (en) 2019-05-22
CA3023819C (en) 2019-10-22
JP2019516699A (ja) 2019-06-20
MA45639B1 (fr) 2020-06-30
KR20190002700A (ko) 2019-01-08
NZ748280A (en) 2020-07-31
AU2016407427A1 (en) 2018-11-22
ES2796181T3 (es) 2020-11-26

Similar Documents

Publication Publication Date Title
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2016009403A (es) Compuestos heterociclicos.
MX2015017215A (es) Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.
PH12016502353A1 (en) Pharmaceutical composition
MD3288940T2 (ro) Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
MD3484467T2 (ro) Combinație de antagoniști ai receptorilor 5-HT6 puri cu inhibitori ai acetilcolinesterazei
TW201613577A (en) Pharmaceutical combinations
MD3265459T2 (ro) Compuși amidici în calitate de agoniști ai receptorilor 5-HT4
NZ744982A (en) Therapeutic compounds
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
MD3458039T2 (ro) Combinație triplă de antagoniști ai receptorilor 5-HT6 puri, inhibitori ai acetilcolinesterazei și antagonistul receptorului NMDA
MX2018013969A (es) Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.
PH12017501736A1 (en) Indole derivatives
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EA202090397A1 (ru) Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора
NZ750150A (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
TN2017000248A1 (en) Cgrp antagonist peptides
MX2019013912A (es) Combinacion de un antagonista del receptor 5-ht6 y un inhibidor de acetilcolinesterasa para su uso en el tratamiento de la enfermedad de alzheimer en una subpoblacion de pacientes portadores de alelos apoe4.